PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America’s Best Large Employers List

RALEIGH, N.C., May 03, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized as the Clinical Research Company of the Year—Americas by PharmaTimes. PRA received the award at a ceremony in Washington, DC. The company has won this award consecutively since 2012.

“We are honored to once again receive this award,” said Michael Brooks, Executive Vice President, Product Registration, Americas. “It is a direct reflection of our incredibly talented team and the professionalism and passion that they bring to their clinical development work.”

PRA was well represented at the competition with more than 60 finalists across the various individual and team categories capturing a total of 11 awards.

Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the contract research organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs, and professional membership associations.

PRA is also pleased to be named on the Forbes 2018 Best Large Employers list. Forbes partnered with market research company Statista to identify the companies liked best by employees. To determine the list, Statista surveyed 30,000 Americans working for businesses with at least 1,000 employees.

ABOUT PRA HEALTH SCIENCES

PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes More than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit www.prahs.com.

Media Inquiries: Christine Rogers, Director, Public Relations, Corporate Communications rogerschristine@prahs.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/991e76ef-a022-455f-a05e-9546cadaa18d